Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Horizon Therapeutics plc

https://www.horizontherapeutics.com

Latest From Horizon Therapeutics plc

Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data

A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj

Inflammation Biologics

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.

Deal Watch Business Strategies

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.

Clinical Trials Business Strategies

Acer’s ‘Misunderstood Drugs’ Strategy Faces Regulatory Hurdles

Acer repurposes drugs with available data (like a 40-year-old European antihypertensive) into rare disease treatments (like Edsivo for vascular Ehlers-Danlos syndrome), but approval remains elusive, with a CRL for ACER-001 just as Edsivo is poised to enter a new clinical trial, armed with a new breakthrough designation. The Pink Sheet delves into regulatory history and strategy with CEO Chris Schelling.

Rare Diseases Complete Response Letters
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Bio-Technology General Corporation
    • Crealta Holdings LLC
    • Crealta Pharmaceuticals
    • Curzion Pharmaceuticals, Inc.
    • Encode Pharmaceuticals, Inc.
    • Horizon Pharma plc
    • Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
    • Nitec Pharma AG
    • Raptor Pharmaceutical Corp.
    • River Vision Development Corp.
    • Savient Pharmaceuticals, Inc. (SVNT)
    • TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
    • Vidara Therapeutics Inc
    • Viela Bio, Inc.
UsernamePublicRestriction

Register